Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498156 | 0.90 | SMPD1 (0.43) | SMPD1SIGMAR1P2RX4PPARAPPARG | |
| SCHEMBL23878783 | 0.84 | RAB9A (0.41) | KMT2ATDP1RAB9A | |
| SCHEMBL29397172 | 0.84 | RAB9A (0.41) | KMT2ATDP1RAB9A | |
| SCHEMBL7625335 | 0.82 | SIGMAR1 (0.44) | SMPD1SIGMAR1P2RX4PPARAPPARG | |
| SCHEMBL7696530 | 0.79 | SIGMAR1 (0.50) | SMPD1SIGMAR1P2RX4PPARAPPARG | |
| SCHEMBL29759083 | 0.79 | SIGMAR1 (0.50) | SMPD1SIGMAR1P2RX4PPARAPPARG | |
| SCHEMBL4821558 | 0.78 | P2RX4 (0.43) | SMPD1SIGMAR1P2RX4PPARAPPARG | |
| SCHEMBL31265092 | 0.78 | PPARA (0.43) | SMPD1SIGMAR1P2RX4PPARAPPARG | |
| SCHEMBL31265099 | 0.78 | PPARA (0.43) | SMPD1SIGMAR1P2RX4PPARAPPARG | |
| SCHEMBL31376392 | 0.78 | PPARG (0.46) | SMPD1SIGMAR1P2RX4PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | SMPD1 343/4885SIGMAR1 2456/4885P2RX4 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.